Coegin Pharma Ab · NGM:COEGIN
Coegin Pharma Ab — Investor Presentation
16 slides from Coegin Pharma Ab's investor presentation
Slide 1: The game changer for stimulation of hair growth and thickness
The game changer for stimulation of hair growth and thickness. www.follicum.com 1
Slide 2: Disclaimer
Disclaimer This presentation contains statements about the future and assumptions about future market conditions, operations, market shares, sales, earnings and milestones. The words “consider”, “intend”, “estimate”, “expect”, “predict”, “plan”, “project” or other related words indicate some of thes
Slide 3: FOL005-peptide gel in brief
FOL005-peptide gel in brief Approximately half of all men and women globally will be affected by hair loss throughout their lives, and wanted is a product that do stimulate hair growth The naturally derived protein osteopontin, is known to be able to stimulate hair growth in humans FOL005-peptide is
Slide 4: Products that are validated to stimulate hair growth are wanted
Products that are validated to stimulate hair growth are wanted 50% of all people will be affected by hair loss Almost half of all men and women globally will be Dark orange, patients with hair loss in USA affected by hair loss throughout their lives Light orange people treated in USA More than 90%
Slide 5: The market opportunity for FOL005
The market opportunity for FOL005 Especially for women there are currently very The current solutions for hair loss consists of limited options both prescription and non-prescription available products, as well as devices, and medical procedures such as hair transplantations FOL005-peptide gel is ex
Slide 6: FOL005-peptide gel is projected capturing double digit market shares
FOL005-peptide gel is projected capturing double digit market shares - US, EU5 (Germany, France, UK, Italy & Spain), China, Japan, and South Korea* 2% market share in 2027, two years after launch 19% market share in 2035, 10 years after launch 2% or 255 thousand 19% or 3.7 million Number of treated
Slide 7: Projected annual peak sales
Projected annual peak sales reaching 600 mEUR in 2040 Forecasted sales Customer base For US, EU5 (Germany, France, UK, Italy & Spain), China, Japan, and South Korea only* Geographical distribution Sales (tEUR) People with hair loss in US and EU5 are expected to make up Year the majority of the FOL00
Slide 8: FOL005-peptide a unique product
FOL005-peptide a unique product FOL005-peptide is a part of the active side of the naturally occurring osteopontin FOL005-peptide is designed for stimulation of hair growth and for stability A unique non-running gel-formulation protects the FOL005-peptide for years at room temperature The packaging
Slide 9: FOL005-peptide gel is clinically proven to stimulate hair growth
FOL005-peptide gel is clinically proven to stimulate hair growth FOL005-peptide gel resulted in 7-12 new hairs per cm 2 after only 4 months of use This equals around 4000 new hairs for a whole scalp (FOL005 0.5%) or almost 40 new hairs on both eyebrows (FOL005 1.5%) 15 * 11,6 Change in total hair de
Slide 10: FOL005-peptide gel is safe
FOL005-peptide gel is safe - Clinical safety data from more than 300 people – Perfect Fit for Cosmetic Use CONCLUSION Overall safety and tolerability of FOL- 005 topical formulation (0.1%, 0.5% and 1.5% strength) was considered as good 313 male persons have been exposed to FOL005 or vehicle either i
Slide 11: Milestone Plan and Capital Demand
Milestone Plan and Capital Demand Total capital demand until the end of 2025: 7 mEUR The goal is to enter licencing deals with leading regional commercial players. www.follicum.com 11
Slide 12: FOL005-peptide Patent Protection
FOL005-peptide Patent Protection WO 2013/021212 • Product claims covering VDTYDGDISVVYGLR (FOL-005) • Method claims for stimulating hair growth www.follicum.com 12
Slide 13: FOL005-peptide gel Patent Protection
FOL005-peptide gel Patent Protection 2020/094797 • Product claims covering a topical formulation of VDTYDGDISVVYGLR (FOL005) www.follicum.com 13
Slide 14: Management and Board of Directors
Management and Board of Directors A very experienced team with +20 years each in pharma, biotech or commercialization Tore Duvold John Zibert Lars Rasmussen Jens Eriksson Jan Nilsson CEO CMO CFO Chairman of the Board Board Member • Extensive experience in • Extensive experience in drug • Extensive e
Slide 15: For more information
"It is a very interesting path that enables the launch of new products based on FOL005 as early as 2025, also with significantly lower development costs. We see great business opportunities for FOL005 as a cosmetic product For more information for people who want to stimulate their hair growth. FOL0
Slide 16: The game changer for stimulation of hair growth and thickness
The game changer for stimulation of hair growth and thickness. www.follicum.com 16